162 related articles for article (PubMed ID: 34257568)
21. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
[TBL] [Abstract][Full Text] [Related]
22. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma.
Nanok C; Jearanaikoon P; Proungvitaya S; Limpaiboon T
Mol Med Rep; 2018 Mar; 17(3):4145-4153. PubMed ID: 29359783
[TBL] [Abstract][Full Text] [Related]
23. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.
Lazareth A; Song XY; Coquin A; Harel S; Karlin L; Belhadj K; Roos-Weil D; Frenzel L; Tamburini J; Macro M; Chevret S; Loiseau HA; Minvielle S; Fermand JP; Soulier J; Bories JC; Arnulf B
Haematologica; 2015 Nov; 100(11):e471-4. PubMed ID: 26206803
[No Abstract] [Full Text] [Related]
24. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
25. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R; Jost E; Braig M; Lohmann F; Mundt F; Barett C; Schlomm T; Sauter G; Senff T; Bokemeyer C; Sültmann H; Meyer-Schwesinger C; Brümmendorf TH; Balabanov S
Mol Cancer; 2011 Oct; 10():129. PubMed ID: 21999842
[TBL] [Abstract][Full Text] [Related]
26. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
[TBL] [Abstract][Full Text] [Related]
27. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
Brito JL; Walker B; Jenner M; Dickens NJ; Brown NJ; Ross FM; Avramidou A; Irving JA; Gonzalez D; Davies FE; Morgan GJ
Haematologica; 2009 Jan; 94(1):78-86. PubMed ID: 19059936
[TBL] [Abstract][Full Text] [Related]
28. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
30. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
Chu L; Su MY; Maggi LB; Lu L; Mullins C; Crosby S; Huang G; Chng WJ; Vij R; Tomasson MH
J Clin Invest; 2012 Aug; 122(8):2793-806. PubMed ID: 22751105
[TBL] [Abstract][Full Text] [Related]
31. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
[TBL] [Abstract][Full Text] [Related]
32. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.
Narita T; Inagaki A; Kobayashi T; Kuroda Y; Fukushima T; Nezu M; Fuchida S; Sakai H; Sekiguchi N; Sugiura I; Maeda Y; Takamatsu H; Tsukamoto N; Maruyama D; Kubota Y; Kojima M; Sunami K; Ono T; Ri M; Tobinai K; Iida S
Blood Cancer J; 2015 Feb; 5(2):e285. PubMed ID: 25723856
[No Abstract] [Full Text] [Related]
33. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
34. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
Onwuazor ON; Wen XY; Wang DY; Zhuang L; Masih-Khan E; Claudio J; Barlogie B; Shaughnessy JD; Stewart AK
Blood; 2003 Jul; 102(2):772-3. PubMed ID: 12835230
[No Abstract] [Full Text] [Related]
35. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
36. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
Walker BA; Wardell CP; Melchor L; Hulkki S; Potter NE; Johnson DC; Fenwick K; Kozarewa I; Gonzalez D; Lord CJ; Ashworth A; Davies FE; Morgan GJ
Blood; 2012 Aug; 120(5):1077-86. PubMed ID: 22573403
[TBL] [Abstract][Full Text] [Related]
37. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
38. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.
Seliger B; Handke D; Schabel E; Bukur J; Lichtenfels R; Dammann R
J Transl Med; 2009 Oct; 7():90. PubMed ID: 19857250
[TBL] [Abstract][Full Text] [Related]
40. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Avet-Loiseau H; Malard F; Campion L; Magrangeas F; Sebban C; Lioure B; Decaux O; Lamy T; Legros L; Fuzibet JG; Michallet M; Corront B; Lenain P; Hulin C; Mathiot C; Attal M; Facon T; Harousseau JL; Minvielle S; Moreau P;
Blood; 2011 Feb; 117(6):2009-11. PubMed ID: 20962323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
